Research

For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.

The WHO has made a draft decision to adopt the neurological Global Action Plan at the 75th World Health Assembly in May 2022.

It is our pleasure to introduce the new EAN Scientific Panels’ Management groups for the 2022-2024 period.

Our research paper of the month is a multicentre, randomised and double-blind phase 2 study with a futility design, exploring the efficacy and the safety of guanabenz in patients with probable or definite amyotrophic lateral sclerosis (ALS).

Our authors of the month conducted a systematic review of SARS-CoV-2-associated deaths in Hamburg, Germany, from March to December 2020, using conventional autopsy, ultrasound-guided minimally invasive autopsy, postmortem computed tomography (PMCT) and medical record review.

Our research paper of the month is an open-label, single-arm, phase II futility trial exploring the safety and the effect of treatment with the antimalarial drug hydroxychloroquine on disability worsening in patients with primary progressive multiple sclerosis.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.

Our research paper of the month is a retrospective cohort study, aiming to investigate the association between field position, professional career length and playing era and increased risk of neurodegenerative disease among male former professional soccer players.

The aim of this study was to describe neurological and psychiatric complications of infection with SARS CoV 2 in children and adolescents and determine the prevalence of such manifestations in hospitalised patients under 18 years-old.

For October 2021, we have selected: Spelman T. el al Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

For October 2021, we have selected: Lopez Bernal J. et al, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant: test-negative case–control study.

Breaking News by Dementia and cognitive disorders Panel

For September 2021, we have selected: Ramsden CE et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial

For September 2021, we have selected: ''Aschman A et al. Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died'' and ''Suh J et al. Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19''

Our research paper of the month is a pooled retrospective non-randomised cohort study, evaluating the functional and safety outcomes of direct to angiography (DTA) treatment paradigm vs repeated imagingin the different treatment windows and on-call hours vs regular hours in patients undergoing thrombectomy.